Tumor lysis syndrome

Summary

Tumor lysis syndrome (MONDO:0043875) is a cancer and 10 clinical trials. Top therapeutic interventions include rasburicase, allopurinol, and febuxostat. A subtype of metabolic disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 10

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	tumor lysis syndrome
Mondo ID	MONDO:0043875
MeSH	D015275
ICD-10-CM	E88.3
NCIT	C3425
SNOMED CT	277605001
UMLS	C0041364
MedGen	52890
GARD	0025870
Is cancer (heuristic)	yes

Also known as: syndrome, tumor lysis · syndrome, tumour lysis · syndromes, tumor lysis · syndromes, tumour lysis · tumor lysis syndrome

Disease family

This is a subtype of metabolic disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › metabolic disease › tumor lysis syndrome

Related subtypes (36): glutaric aciduria, mineral metabolism disease, xanthinuria, chondrocalcinosis, ochronosis disorder, glucose metabolism disease, diabetic kidney disease, xanthoma, diabetic retinopathy, hypertriglyceridemia, gout, lactic acidosis, acquired metabolic disease, lipodystrophy, developmental anomaly of metabolic origin, dopa-responsive dystonia, hypoalphalipoproteinemia, steroid dehydrogenase deficiency-dental anomalies syndrome, inborn errors of metabolism, vitamin B12 deficiency, proteostasis deficiencies, hyperlipidemia, disorder of GPI anchor biosynthesis, bilirubin metabolism disease, hyperlipoproteinemia, carbohydrate metabolism disease, porphyrin metabolism disease, purine metabolism disease, amino acid metabolism disease, pyrimidine metabolism disease, disorder of acid-base balance, disorder of glutamate decarboxylase, collagenous sprue, steroid metabolism disease, disorder of organic acid metabolism, skeletal fluorosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Allopurinol	Phase 3 (in late-stage trials)
Febuxostat	Phase 3 (in late-stage trials)
Rasburicase	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 10.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE4	3
PHASE3	2
PHASE1/PHASE2	2
Not specified	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00230217	PHASE4	COMPLETED	Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
NCT00651911	PHASE4	COMPLETED	Fasturtec TLS Treatment / Prophylysis
NCT04745910	PHASE4	COMPLETED	Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome
NCT00230178	PHASE3	COMPLETED	Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
NCT01724528	PHASE3	COMPLETED	Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies
NCT00360438	PHASE1/PHASE2	COMPLETED	Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
NCT00628628	PHASE2	COMPLETED	Rasburicase in Patients at Risk for Tumor Lysis Syndrome
NCT03605212	PHASE1/PHASE2	TERMINATED	Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
NCT00186940	Not specified	COMPLETED	Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
NCT01097369	Not specified	TERMINATED	Elitek (Rasburicase) Immuno-Monitoring Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
RASBURICASE	4	6
ALLOPURINOL	4	2
FEBUXOSTAT	4	2
PEGLOTICASE	4	1